These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9280669)

  • 21. Does oxybutynin alter plaques, amyloid beta peptides and behavior in a mouse model of Alzheimer's disease?
    Klausner AP; Sharma S; Fletcher S; Neff P; Yang SK; Son H; Tuttle JB; Steers WD
    J Urol; 2008 Mar; 179(3):1173-7. PubMed ID: 18206173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Oxidative stress, beta-amyloide peptide and Alzheimer's disease].
    Manzano-León N; Mas-Oliva J
    Gac Med Mex; 2006; 142(3):229-38. PubMed ID: 16875352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease.
    Schmidt AM; Sahagan B; Nelson RB; Selmer J; Rothlein R; Bell JM
    Curr Opin Investig Drugs; 2009 Jul; 10(7):672-80. PubMed ID: 19579173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic treatments for Alzheimer's disease based on metal bioavailability.
    Crouch PJ; Barnham KJ; Bush AI; White AR
    Drug News Perspect; 2006 Oct; 19(8):469-74. PubMed ID: 17160147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Canine cognitive dysfunction and the cerebellum: acetylcholinesterase reduction, neuronal and glial changes.
    Pugliese M; Gangitano C; Ceccariglia S; Carrasco JL; Del Fà A; Rodríguez MJ; Michetti F; Mascort J; Mahy N
    Brain Res; 2007 Mar; 1139():85-94. PubMed ID: 17292335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.
    Hardy J; Selkoe DJ
    Science; 2002 Jul; 297(5580):353-6. PubMed ID: 12130773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human amylin actions on rat cholinergic basal forebrain neurons: antagonism of beta-amyloid effects.
    Jhamandas JH; Harris KH; Cho C; Fu W; MacTavish D
    J Neurophysiol; 2003 Jun; 89(6):2923-30. PubMed ID: 12611974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade.
    Takada-Takatori Y; Kume T; Sugimoto M; Katsuki H; Sugimoto H; Akaike A
    Neuropharmacology; 2006 Sep; 51(3):474-86. PubMed ID: 16762377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How Anticholinergic Drugs Might Promote Alzheimer's Disease: More Amyloid-β and Less Phosphatidylcholine.
    Wurtman RJ
    J Alzheimers Dis; 2015; 46(4):983-7. PubMed ID: 26402628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Current theories on the etiopathogenesis and treatment of Alzheimer's disease].
    Bidzan L
    Psychiatr Pol; 1986; 20(5):377-85. PubMed ID: 3295924
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited.
    Ladner CJ; Lee JM
    J Neuropathol Exp Neurol; 1998 Aug; 57(8):719-31. PubMed ID: 9720487
    [No Abstract]   [Full Text] [Related]  

  • 32. [Central effect of calcium channel antagonists: new therapeutic possibilities in neurology and psychiatry?].
    Kostowski W; Puciłowski O
    Psychiatr Pol; 1990; 24(3):209-16. PubMed ID: 2084729
    [No Abstract]   [Full Text] [Related]  

  • 33. Anticholinergic Activity and Alzheimer's Disease.
    Hori K; Hachisu M; Tomioka H; Konishi K
    Neurodegener Dis; 2015; 15(3):131-3. PubMed ID: 26138489
    [No Abstract]   [Full Text] [Related]  

  • 34. Nicotinic treatment of Alzheimer's disease.
    Newhouse PA; Potter A; Kelton M; Corwin J
    Biol Psychiatry; 2001 Feb; 49(3):268-78. PubMed ID: 11230878
    [No Abstract]   [Full Text] [Related]  

  • 35. Is a potential Alzheimer's therapy already in use for other conditions? Can medications for hypertension, diabetes and acne help with the symptoms?
    Corbett A; Ballard C
    Expert Opin Investig Drugs; 2013 Aug; 22(8):941-3. PubMed ID: 23808708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cholinergic precursors in Alzheimer's disease.
    Pomara N; Stanley M
    Lancet; 1982 Nov; 2(8306):1049. PubMed ID: 6127534
    [No Abstract]   [Full Text] [Related]  

  • 37. Convergence of atherosclerosis and Alzheimer's disease.
    Korantzopoulos P; Kokkoris S; Siogas K; Galaris D
    Lancet; 2004 Jun; 363(9426):2092. PubMed ID: 15207975
    [No Abstract]   [Full Text] [Related]  

  • 38. Anticholinergic agents.
    Cazzola M; Centanni S; Donner CF
    Pulm Pharmacol Ther; 1998; 11(5-6):381-92. PubMed ID: 10210656
    [No Abstract]   [Full Text] [Related]  

  • 39. Serum Anticholinergic Activity as an Index of Anticholinergic Activity Load in Alzheimer's Disease.
    Hachisu M; Konishi K; Hosoi M; Tani M; Tomioka H; Kitajima Y; Inamoto A; Hirata A; Koganemaru T; Tomita A; Akashi N; Hori K
    Neurodegener Dis; 2015; 15(3):134-9. PubMed ID: 26138490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical results with nimodipine in Alzheimer disease.
    Grobe-Einsler R; Traber J
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():416A-417A. PubMed ID: 1323399
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.